Studies longziekten
Op de dienst longziekten doen we onderzoek naar betere en steeds meer doeltreffende behandelingen van patiënten met verschillende longaandoeningen. Er lopen dan ook verschillende klinische studies op onze dienst. In klinische studies wordt onderzocht welke behandelingen veiliger, effectiever en beter zijn dan de bestaande behandelingen. Het studieteam van de dienst longziekten bestaat uit longartsen die nauw samen werken met studiecoördinatoren, longfunctietechnici, verpleegkundigen en administratieve medewerkers.
Hoe kan ik kenbaar maken dat ik interesse heb in deelname aan een studie op de dienst longziekten?
Heeft u interesse in deelname aan een studie die loopt op de dienst longziekten, of heeft u een vraag over een bepaalde studie? Neem dan vrijblijvend contact op via studie [dot] longziekten [at] uza [dot] be.
| Study name | Title | Diagnosis | Recruitment criteria | Registry | Status |
| BE-REAL | Patient-reported outcomes in real-world use of benralizumab in patients with severe eosinophilic asthma in Belgium. A multicentre, single arm, observational, prospective study to assess demographic characteristics, burden of disease and patient reported outcomes in uncontrolled, severe eosinophilic asthma patients aged 18 years or older and qualifying for treatment with benralizumab in Belgium | Severe eosinophilic asthma |
|
NCT04221802 | Open |
| PuRE-COVID | Changes in functional exercise capacity after PUlmonary REhabilitation in primary care: a randomized, controlled, multicenter, pragmatic trial in 134 patients with long COVID (PuRe-COVID). | Long COVID |
|
NCT05244044 | Open |
| RESOLUTE | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils |
Moderate to very severe COPD with history of exacerbations |
|
NCT04053634 | Open |
|
RPL554-CO-302 |
A Phase III Randomized, double-blind, placebo-controlled study to evaluate the effcacy and safety of ensifentrine over 24 weeks in subjects with moderate to very severe COPD | Moderate to very severe COPD |
|
NCT04535986 | Open |
|
BREAMAT
|
The use of breathomics to monitor patients with severe asthma during biological treatment: an evolving algorithm? | Severe asthma |
|
Open | |
|
INS-1007-301 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis |
Non-CF bronchiëctasis |
|
NCT04594369 | Open |
